Fate Therapeutics (FATE)
(Real Time Quote from BATS)
$3.99 USD
-0.15 (-3.62%)
Updated May 17, 2024 11:26 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
Fate Therapeutics, Inc. [FATE]
Reports for Purchase
Showing records 281 - 300 ( 426 total )
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Results: FT500 IND Submission Expected 2Q18
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q18 Financials; IND Submission for FT500 in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Early APOLLO Update in Ovarian Cancer Shows Signs of Clinical Activity
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Announces Initial Encouraging Clinical Data for FATE-NK100; Reiterate Hold
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Fate Announces Updated Data From Phase 1 of PROTECT; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ph 1 PROTECT Update: Ongoing Relapse-Free States Key Positive
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q17 Results: Moving to the Sidelines After Recent Boost; Downgrading to Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
4Q/YE17 Financials; Increasing Price Target on Continued NK100 Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Fate Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.